Skip to main content
Top
Published in: Clinical and Experimental Medicine 3/2020

01-08-2020 | Breast Cancer | Original Article

MicroRNA-4317 predicts the prognosis of breast cancer and inhibits tumor cell proliferation, migration, and invasion

Authors: Yuwei Sheng, Rong Hu, Yi Zhang, Wenjie Luo

Published in: Clinical and Experimental Medicine | Issue 3/2020

Login to get access

Abstract

Previous researches have indicated that miR-4317 was aberrantly expressed in several tumors. However, the potential role of miR-4317 in breast cancer is still unclear. The aim of this study was to investigate the potential role of miR-4317 in breast cancer. The relative expression levels of miR-4317 were detected in breast cancer tissues and cell lines using qRT-PCR analysis. The Kaplan–Meier survival curve and multivariate Cox regression analyses were used to investigate the prognostic significance of miR-4317 in breast cancer. CCK-8 and Transwell assays were performed to evaluate the effects of miR-4317 on cell proliferation, migration, and invasion. The results showed that miR-4317 expression was decreased in breast cancer tissues and cell lines. Downregulation of miR-4317 was significantly associated with lymph node metastasis, TNM stage, and poor prognosis. Overexpression of miR-4317 inhibited proliferation, migration, and invasion of breast cancer cells, while downregulation of miR-4317 exhibited the opposite effects. MYD88 may be a direct target of miR-4317. The results suggest miR-4317 may play a tumor suppressor role in breast cancer and inhibit proliferation, migration, and invasion of breast cancer cells by targeting MYD88. The findings provide novel evidence of miR-4317 as a potential prognostic biomarker and therapeutic target for breast cancer.
Literature
2.
go back to reference Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRef Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRef
3.
go back to reference Zhou D, Ouyang Q, Liu L, et al. Chemotherapy modulates endocrine therapy-related resistance mutations in metastatic breast cancer. Transl Oncol. 2019;12(5):764–74.PubMedPubMedCentralCrossRef Zhou D, Ouyang Q, Liu L, et al. Chemotherapy modulates endocrine therapy-related resistance mutations in metastatic breast cancer. Transl Oncol. 2019;12(5):764–74.PubMedPubMedCentralCrossRef
5.
go back to reference de Castro Sant’ Anna C, Junior AGF, Soares P, et al. Molecular biology as a tool for the treatment of cancer. Clin Exp Med. 2018;18(4):457–64.PubMedCrossRef de Castro Sant’ Anna C, Junior AGF, Soares P, et al. Molecular biology as a tool for the treatment of cancer. Clin Exp Med. 2018;18(4):457–64.PubMedCrossRef
6.
go back to reference Jiang L, Zhang X, Geradts J, et al. Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker. Clin Exp Med. 2019;19(3):377–84.PubMedCrossRef Jiang L, Zhang X, Geradts J, et al. Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker. Clin Exp Med. 2019;19(3):377–84.PubMedCrossRef
7.
go back to reference Campos CZ, Losi Guembarovski R, de Oliveira CEC, et al. Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer. Clin Exp Med. 2018;18(1):27–35.PubMedCrossRef Campos CZ, Losi Guembarovski R, de Oliveira CEC, et al. Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer. Clin Exp Med. 2018;18(1):27–35.PubMedCrossRef
8.
9.
go back to reference Chen H, Yang Y, Wang J, Shen D, Zhao J, Yu Q. miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1. Oncol Lett. 2018;15(5):6361–7.PubMedPubMedCentral Chen H, Yang Y, Wang J, Shen D, Zhao J, Yu Q. miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1. Oncol Lett. 2018;15(5):6361–7.PubMedPubMedCentral
10.
go back to reference Sun X, Cui S, Fu X, Liu C, Wang Z, Liu Y. MicroRNA-146-5p promotes proliferation, migration and invasion in lung cancer cells by targeting claudin-12. Cancer Biomark. 2019;25(1):89–99.PubMedCrossRef Sun X, Cui S, Fu X, Liu C, Wang Z, Liu Y. MicroRNA-146-5p promotes proliferation, migration and invasion in lung cancer cells by targeting claudin-12. Cancer Biomark. 2019;25(1):89–99.PubMedCrossRef
11.
go back to reference Guo H, Zhang L. MicroRNA-30a suppresses papillary thyroid cancer cell proliferation, migration and invasion by directly targeting E2F7. Exp Ther Med. 2019;18(1):209–15.PubMedPubMedCentral Guo H, Zhang L. MicroRNA-30a suppresses papillary thyroid cancer cell proliferation, migration and invasion by directly targeting E2F7. Exp Ther Med. 2019;18(1):209–15.PubMedPubMedCentral
12.
go back to reference Liu Y, Duan N, Duan S. MiR-29a inhibits glioma tumorigenesis through a negative feedback loop of TRAF4/Akt signaling. Biomed Res Int. 2018;2018:2461363.PubMedPubMedCentral Liu Y, Duan N, Duan S. MiR-29a inhibits glioma tumorigenesis through a negative feedback loop of TRAF4/Akt signaling. Biomed Res Int. 2018;2018:2461363.PubMedPubMedCentral
13.
go back to reference Huang GH, Shan H, Li D, Zhou B, Pang PF. MiR-199a-5p suppresses tumorigenesis by targeting clathrin heavy chain in hepatocellular carcinoma. Cell Biochem Funct. 2017;35(2):98–104.PubMedCrossRef Huang GH, Shan H, Li D, Zhou B, Pang PF. MiR-199a-5p suppresses tumorigenesis by targeting clathrin heavy chain in hepatocellular carcinoma. Cell Biochem Funct. 2017;35(2):98–104.PubMedCrossRef
14.
go back to reference Hannafon BN, Cai A, Calloway CL, et al. miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study. BMC Cancer. 2019;19(1):642.PubMedPubMedCentralCrossRef Hannafon BN, Cai A, Calloway CL, et al. miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study. BMC Cancer. 2019;19(1):642.PubMedPubMedCentralCrossRef
15.
go back to reference Zhao C, Ling X, Li X, Hou X, Zhao D. MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1. Breast Cancer. 2019;26(6):817–25.PubMedCrossRef Zhao C, Ling X, Li X, Hou X, Zhao D. MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1. Breast Cancer. 2019;26(6):817–25.PubMedCrossRef
16.
go back to reference Zhao XG, Hu JY, Tang J, et al. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 2019;10(7):479.PubMedPubMedCentralCrossRef Zhao XG, Hu JY, Tang J, et al. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 2019;10(7):479.PubMedPubMedCentralCrossRef
17.
go back to reference Sand M, Skrygan M, Sand D, et al. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013;351(1):85–98.PubMedCrossRef Sand M, Skrygan M, Sand D, et al. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013;351(1):85–98.PubMedCrossRef
18.
go back to reference Janiszewska J, Szaumkessel M, Kostrzewska-Poczekaj M, et al. Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma. PLoS ONE. 2015;10(12):e0144924.PubMedPubMedCentralCrossRef Janiszewska J, Szaumkessel M, Kostrzewska-Poczekaj M, et al. Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma. PLoS ONE. 2015;10(12):e0144924.PubMedPubMedCentralCrossRef
19.
go back to reference Danza K, De Summa S, Pilato B, et al. Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. J Transl Med. 2014;12:319.PubMedPubMedCentralCrossRef Danza K, De Summa S, Pilato B, et al. Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. J Transl Med. 2014;12:319.PubMedPubMedCentralCrossRef
20.
go back to reference Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol. 2015;12(3):147–62.PubMedCrossRef Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol. 2015;12(3):147–62.PubMedCrossRef
21.
go back to reference Hart NH, Galvao DA, Saunders C, et al. Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine. Trials. 2018;19(1):695.PubMedPubMedCentralCrossRef Hart NH, Galvao DA, Saunders C, et al. Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine. Trials. 2018;19(1):695.PubMedPubMedCentralCrossRef
22.
go back to reference Liu L, Tian YC, Mao G, Zhang YG, Han L. MiR-675 is frequently overexpressed in gastric cancer and enhances cell proliferation and invasion via targeting a potent anti-tumor gene PITX1. Cell Signal. 2019;62:109352.PubMedCrossRef Liu L, Tian YC, Mao G, Zhang YG, Han L. MiR-675 is frequently overexpressed in gastric cancer and enhances cell proliferation and invasion via targeting a potent anti-tumor gene PITX1. Cell Signal. 2019;62:109352.PubMedCrossRef
23.
go back to reference Zhang L, Xu J, Yang G, Li H, Guo X. miR-202 inhibits cell proliferation, migration, and invasion by targeting epidermal growth factor receptor in human bladder cancer. Oncol Res. 2018;26(6):949–57.PubMedCrossRef Zhang L, Xu J, Yang G, Li H, Guo X. miR-202 inhibits cell proliferation, migration, and invasion by targeting epidermal growth factor receptor in human bladder cancer. Oncol Res. 2018;26(6):949–57.PubMedCrossRef
24.
go back to reference Yang W, Bai J, Liu D, et al. MiR-93-5p up-regulation is involved in non-small cell lung cancer cells proliferation and migration and poor prognosis. Gene. 2018;647:13–20.PubMedCrossRef Yang W, Bai J, Liu D, et al. MiR-93-5p up-regulation is involved in non-small cell lung cancer cells proliferation and migration and poor prognosis. Gene. 2018;647:13–20.PubMedCrossRef
25.
go back to reference Wu M, Li X, Liu Q, Xie Y, Yuan J, Wanggou S. miR-526b-3p serves as a prognostic factor and regulates the proliferation, invasion, and migration of glioma through targeting WEE1. Cancer Manag Res. 2019;11:3099–110.PubMedPubMedCentralCrossRef Wu M, Li X, Liu Q, Xie Y, Yuan J, Wanggou S. miR-526b-3p serves as a prognostic factor and regulates the proliferation, invasion, and migration of glioma through targeting WEE1. Cancer Manag Res. 2019;11:3099–110.PubMedPubMedCentralCrossRef
27.
go back to reference Li C, Zhang J, Ma Z, Zhang F, Yu W. miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. Onco Targets Ther. 2018;11:4087–95.PubMedPubMedCentralCrossRef Li C, Zhang J, Ma Z, Zhang F, Yu W. miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. Onco Targets Ther. 2018;11:4087–95.PubMedPubMedCentralCrossRef
28.
go back to reference Li WJ, Xie XX, Bai J, Wang C, Zhao L, Jiang DQ. Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis. Eur Rev Med Pharmacol Sci. 2018;22(23):8374–82.PubMed Li WJ, Xie XX, Bai J, Wang C, Zhao L, Jiang DQ. Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis. Eur Rev Med Pharmacol Sci. 2018;22(23):8374–82.PubMed
29.
go back to reference Zhang J, He Y, Yu Y, et al. Upregulation of miR-374a promotes tumor metastasis and progression by downregulating LACTB and predicts unfavorable prognosis in breast cancer. Cancer Med. 2018;7(7):3351–62.PubMedCentralCrossRef Zhang J, He Y, Yu Y, et al. Upregulation of miR-374a promotes tumor metastasis and progression by downregulating LACTB and predicts unfavorable prognosis in breast cancer. Cancer Med. 2018;7(7):3351–62.PubMedCentralCrossRef
30.
go back to reference Zhang J, Tian ZL, Zhang WT, et al. Clinicopathological and prognostic significance of miR-4317 expression in gastric cancer patients. Eur Rev Med Pharmacol Sci. 2019;23(7):2803–8.PubMed Zhang J, Tian ZL, Zhang WT, et al. Clinicopathological and prognostic significance of miR-4317 expression in gastric cancer patients. Eur Rev Med Pharmacol Sci. 2019;23(7):2803–8.PubMed
31.
go back to reference He X, Chen SY, Yang Z, et al. miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2). J Exp Clin Cancer Res. 2018;37(1):230.PubMedPubMedCentralCrossRef He X, Chen SY, Yang Z, et al. miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2). J Exp Clin Cancer Res. 2018;37(1):230.PubMedPubMedCentralCrossRef
32.
go back to reference Hu X, Zhang M, Miao J, Wang X, Huang C. miRNA-4317 suppresses human gastric cancer cell proliferation by targeting ZNF322. Cell Biol Int. 2018;42(8):923–30.PubMedCrossRef Hu X, Zhang M, Miao J, Wang X, Huang C. miRNA-4317 suppresses human gastric cancer cell proliferation by targeting ZNF322. Cell Biol Int. 2018;42(8):923–30.PubMedCrossRef
33.
go back to reference Xu X, Yin Y, Tang J, et al. Long non-coding RNA Myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating Myd88 expression through H3K27 modification. Cell Death Dis. 2017;8(10):e3124.PubMedPubMedCentralCrossRef Xu X, Yin Y, Tang J, et al. Long non-coding RNA Myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating Myd88 expression through H3K27 modification. Cell Death Dis. 2017;8(10):e3124.PubMedPubMedCentralCrossRef
34.
go back to reference Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–9.PubMedCrossRef Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–9.PubMedCrossRef
35.
go back to reference Xiang F, Ni Z, Zhan Y, et al. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer. Tumour Biol. 2016;37(5):6017–25.PubMedCrossRef Xiang F, Ni Z, Zhan Y, et al. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer. Tumour Biol. 2016;37(5):6017–25.PubMedCrossRef
Metadata
Title
MicroRNA-4317 predicts the prognosis of breast cancer and inhibits tumor cell proliferation, migration, and invasion
Authors
Yuwei Sheng
Rong Hu
Yi Zhang
Wenjie Luo
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 3/2020
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-020-00625-4

Other articles of this Issue 3/2020

Clinical and Experimental Medicine 3/2020 Go to the issue